598: Neil Clark & Shaun Claydon of Destiny Pharma: new funds will progress two lead clinical assets towards Phase 3 trials
Neil Clark, CEO & Shaun Claydon, CFO of Destiny Pharma #DEST explain how their funds raised continue progress towards Phase 3 trials in its two lead, clinical assets, NTCD-M3 and XF-73 Nasal, and finalise regulatory plans, whilst also strengthening the balance sheet as the Company progresses partnering discussions in relation to NTCD-M3.
6m
•
Mar 09, 2022